Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R; BHIVES Collaborative. Altice FL, et al. Among authors: lucas gm. J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1(Suppl 1):S22-32. doi: 10.1097/QAI.0b013e318209751e. J Acquir Immune Defic Syndr. 2011. PMID: 21317590 Free PMC article. Clinical Trial.
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.
Metzger DS, Donnell D, Celentano DD, Jackson JB, Shao Y, Aramrattana A, Wei L, Fu L, Ma J, Lucas GM, Chawarski M, Ruan Y, Richardson P, Shin K, Chen RY, Sugarman J, Dye BJ, Rose SM, Beauchamp G, Burns DN; HPTN 058 Protocol Team. Metzger DS, et al. Among authors: lucas gm. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):554-61. doi: 10.1097/QAI.0000000000000510. J Acquir Immune Defic Syndr. 2015. PMID: 25564105 Free PMC article. Clinical Trial.
Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.
Cook RR, Torralva R, King C, Lum PJ, Tookes H, Foot C, Vergara-Rodriguez P, Rodriguez A, Fanucchi L, Lucas GM, Waddell EN, Korthuis PT. Cook RR, et al. Among authors: lucas gm. Drug Alcohol Depend. 2021 Nov 1;228:109077. doi: 10.1016/j.drugalcdep.2021.109077. Epub 2021 Sep 20. Drug Alcohol Depend. 2021. PMID: 34600253 Free PMC article. Clinical Trial.
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Korthuis PT, Cook RR, Lum PJ, Waddell EN, Tookes H, Vergara-Rodriguez P, Kunkel LE, Lucas GM, Rodriguez AE, Bielavitz S, Fanucchi LC, Hoffman KA, Bachrach K, Payne EH, Collins JA, Matthews A, Oden N, Jacobs P, Jelstrom E, Sorensen JL, McCarty D. Korthuis PT, et al. Among authors: lucas gm. Addiction. 2022 Jul;117(7):1961-1971. doi: 10.1111/add.15836. Epub 2022 Mar 2. Addiction. 2022. PMID: 35129242 Free PMC article. Clinical Trial.
190 results